News & Updates
Filter by Specialty:
Obesity persists in axSpA, especially in socially deprived patients
Obesity appears to be prevalent among patients with axial spondyloarthritis (axSpA) compared to the general population, according to a Swiss study, noting that socially disadvantaged individuals are most affected by this comorbidity.
Obesity persists in axSpA, especially in socially deprived patients
11 Dec 2023
Cholesterol-rich diet, variants of metabolism genes predict GDM development
A diet rich in cholesterol during early pregnancy and genetic variations of cholesterol metabolism genes both contribute to the risk of gestational diabetes mellitus (GDM), suggests a study.
Cholesterol-rich diet, variants of metabolism genes predict GDM development
07 Dec 2023
Alanine tied to diabetes, BP, lipid profile but not CAD
Plasma alanine or factors affecting alanine appear to contribute to an increased risk of diabetes, higher blood glucose, low-density lipoprotein cholesterol (LDL-C), and blood pressure (BP), but not coronary artery disease (CAD), reports a study.
Alanine tied to diabetes, BP, lipid profile but not CAD
07 Dec 2023
Community intervention helps improve diet patterns, wellbeing of women
A cardiovascular disease (CVD) risk reduction intervention, the Strong Hearts, Healthy Communities 2.0 (SHHC-2.0), may be useful among midlife and older female adults of rural communities in improving their diet patterns and diet-related psychosocial wellbeing consistent with improved cardiovascular health, according to a study.
Community intervention helps improve diet patterns, wellbeing of women
06 Dec 2023
Slow walk pace, weight gain up CKD risk in adults with obesity
Weight gain and a slow walking pace both influence the risk of chronic kidney disease among adults with obesity who do not have diabetes at baseline, results of a study have shown.
Slow walk pace, weight gain up CKD risk in adults with obesity
03 Dec 2023
Novel tri-agonist confers significant gains for MASLD patients
In a substudy of a phase II obesity trial, individuals with MASLD* and obesity benefited significantly from retatrutide, a once-weekly, injectable, novel synthetic molecule that has shown potent agonist action at GIP**, GLP-1***, and glucagon receptors.